NCT01068639撤回不适用
IMprove PAtient Compliance sTudy: An Observational, Cross-sectional Study on Children Treated With Growth Hormone in France
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Average number of injections omitted during the previous month
研究概览
简要总结
This study is conducted in Europe. This observational study aims at evaluating compliance with growth hormone treatment in children and identifying factors influencing compliance.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- — 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Child treated for at least one year with growth hormone any growth hormone product
- •Followed by the participating paediatrician for at least 1 year.
排除标准
- •Refusal to participate
- •Child and/or parent unable to give consent or fill out the questionnaires
- •Child participating in a therapeutic trial
结局指标
主要结局
Average number of injections omitted during the previous month
时间窗: measured over the past 2 months (retrospective data collection)
次要结局
未报告次要终点
研究者
相似试验
终止
不适用
Lexington Observational Study of Treatment With Compounded Pain CreamsChronic PainAcute PainNCT02195752Lexington Independent Studies, LLC26
已完成
不适用
A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected MelanomaMelanomaNCT01986712St. Luke's Hospital and Health Network, Pennsylvania50
已完成
不适用
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for InhalationPulmonary HypertensionNCT01894035Bayer13
已完成
不适用
AdHerencE to Treatment and quAlity of Life in COPDCompliance, PatientQuality of LifeChronic Obstructive Pulmonary DiseaseNCT03299673Elpen Pharmaceutical Co. Inc.600
已完成
4 期
Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND OptimisationChronic Myelogenous Leukemia (CML)NCT01243489Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH104